K-V Pharmaceutical to divest generics business to Zydus for $60 million

| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
ST. LOUIS—K-V Pharmaceutical Co.announced today that it has entered into a definitive agreement todivest Nesher Pharmaceuticals Inc., its generics subsidiary, and thecompany's generic business and assets, to Zydus Pharmaceuticals (USA)Inc. for approximately $60 million in cash. The transaction isestimated to close during the second quarter of KV's 2012 fiscalyear, subject to customary closing conditions.

The divesture of the company's genericbusiness has been "an important goal of KV's board of directors andmanagement team," according to the company, with the divestiturebeing an important element of the company's declared strategy oftransitioning to a branded specialty pharmaceutical company focusedon women's health.

Jefferies & Company, Inc. acted asexclusive financial advisor to K-V in this transaction.
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue